BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 25311422)

  • 1. Hyaluronic acid oligosaccharide modified redox-responsive mesoporous silica nanoparticles for targeted drug delivery.
    Zhao Q; Geng H; Wang Y; Gao Y; Huang J; Wang Y; Zhang J; Wang S
    ACS Appl Mater Interfaces; 2014 Nov; 6(22):20290-9. PubMed ID: 25311422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual-stimuli responsive hyaluronic acid-conjugated mesoporous silica for targeted delivery to CD44-overexpressing cancer cells.
    Zhao Q; Liu J; Zhu W; Sun C; Di D; Zhang Y; Wang P; Wang Z; Wang S
    Acta Biomater; 2015 Sep; 23():147-156. PubMed ID: 25985912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PEGylated mesoporous silica as a redox-responsive drug delivery system for loading thiol-containing drugs.
    Zhao Q; Wang C; Liu Y; Wang J; Gao Y; Zhang X; Jiang T; Wang S
    Int J Pharm; 2014 Dec; 477(1-2):613-22. PubMed ID: 25445534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multifunctional mesoporous silica nanoparticles modified with tumor-shedable hyaluronic acid as carriers for doxorubicin.
    Zhang J; Sun Y; Tian B; Li K; Wang L; Liang Y; Han J
    Colloids Surf B Biointerfaces; 2016 Aug; 144():293-302. PubMed ID: 27107383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. γ-PGA-coated mesoporous silica nanoparticles with covalently attached prodrugs for enhanced cellular uptake and intracellular GSH-responsive release.
    Du X; Xiong L; Dai S; Qiao SZ
    Adv Healthc Mater; 2015 Apr; 4(5):771-81. PubMed ID: 25582379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells.
    Yu M; Jambhrunkar S; Thorn P; Chen J; Gu W; Yu C
    Nanoscale; 2013 Jan; 5(1):178-83. PubMed ID: 23076766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorescent carbon dot-gated multifunctional mesoporous silica nanocarriers for redox/enzyme dual-responsive targeted and controlled drug delivery and real-time bioimaging.
    Wang Y; Cui Y; Zhao Y; He B; Shi X; Di D; Zhang Q; Wang S
    Eur J Pharm Biopharm; 2017 Aug; 117():105-115. PubMed ID: 28363599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyaluronic acid and carbon dots-gated hollow mesoporous silica for redox and enzyme-triggered targeted drug delivery and bioimaging.
    Zhao Q; Wang S; Yang Y; Li X; Di D; Zhang C; Jiang T; Wang S
    Mater Sci Eng C Mater Biol Appl; 2017 Sep; 78():475-484. PubMed ID: 28576012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redox-responsive mesoporous silica as carriers for controlled drug delivery: a comparative study based on silica and PEG gatekeepers.
    Wang Y; Han N; Zhao Q; Bai L; Li J; Jiang T; Wang S
    Eur J Pharm Sci; 2015 May; 72():12-20. PubMed ID: 25701727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Redox/pH dual stimuli-responsive ZnO QDs-gated mesoporous silica nanoparticles as carriers in cancer therapy.
    Wang W; Wang Y; Wang Y; Gong H; Zhu H; Liu M
    IET Nanobiotechnol; 2019 Aug; 13(6):640-649. PubMed ID: 31432799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles.
    Fan J; Fang G; Wang X; Zeng F; Xiang Y; Wu S
    Nanotechnology; 2011 Nov; 22(45):455102. PubMed ID: 22019849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyaluronic acid modified mesoporous carbon nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells.
    Wan L; Jiao J; Cui Y; Guo J; Han N; Di D; Chang D; Wang P; Jiang T; Wang S
    Nanotechnology; 2016 Apr; 27(13):135102. PubMed ID: 26901756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesoporous silica nanoparticles capped with disulfide-linked PEG gatekeepers for glutathione-mediated controlled release.
    Cui Y; Dong H; Cai X; Wang D; Li Y
    ACS Appl Mater Interfaces; 2012 Jun; 4(6):3177-83. PubMed ID: 22646097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD44-specific nanoparticles for redox-triggered reactive oxygen species production and doxorubicin release.
    Lin CW; Lu KY; Wang SY; Sung HW; Mi FL
    Acta Biomater; 2016 Apr; 35():280-92. PubMed ID: 26853764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced Efficacy against Drug-Resistant Tumors Enabled by Redox-Responsive Mesoporous-Silica-Nanoparticle-Supported Lipid Bilayers as Targeted Delivery Vehicles.
    Yang S; Zhang B; Zhao X; Zhang M; Zhang M; Cui L; Zhang L
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioresponsive hyaluronic acid-capped mesoporous silica nanoparticles for targeted drug delivery.
    Chen Z; Li Z; Lin Y; Yin M; Ren J; Qu X
    Chemistry; 2013 Jan; 19(5):1778-83. PubMed ID: 23303570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of mesoporous silica nanoparticles and mesoporous organosilica nanoparticles as drug vehicles for cancer therapy.
    Yue J; Luo SZ; Lu MM; Shao D; Wang Z; Dong WF
    Chem Biol Drug Des; 2018 Aug; 92(2):1435-1444. PubMed ID: 29671941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytochrome c end-capped mesoporous silica nanoparticles as redox-responsive drug delivery vehicles for liver tumor-targeted triplex therapy in vitro and in vivo.
    Zhang B; Luo Z; Liu J; Ding X; Li J; Cai K
    J Control Release; 2014 Oct; 192():192-201. PubMed ID: 25034575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Host-guest fabrication of dual-responsive hyaluronic acid/mesoporous silica nanoparticle based drug delivery system for targeted cancer therapy.
    Lu J; Luo B; Chen Z; Yuan Y; Kuang Y; Wan L; Yao L; Chen X; Jiang B; Liu J; Li C
    Int J Biol Macromol; 2020 Mar; 146():363-373. PubMed ID: 31911174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesoporous silica nanoparticles end-capped with collagen: redox-responsive nanoreservoirs for targeted drug delivery.
    Luo Z; Cai K; Hu Y; Zhao L; Liu P; Duan L; Yang W
    Angew Chem Int Ed Engl; 2011 Jan; 50(3):640-3. PubMed ID: 21226142
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.